Acclinate

Acclinate has demonstrated rapid growth and significant traction in the digital health sector by enabling more inclusive clinical research. Its platforms have been adopted by major pharmaceutical companies to improve minority representation in clinical trials. The company was ranked #539 on the Inc. 5000 list in 2024 with an 823% three-year growth rate and recently raised $7 million in Series A funding. It has established partnerships with Merck, Roche, Johnson & Johnson Innovation/Trialbee, and others to increase diversity in studies for cancer drugs and lupus therapies. No direct clinical results as it does not sponsor or run its own interventional studies.